|
|||||
![]() |
|
Young adult apparel retailer Abercrombie & Fitch (NYSE:ANF) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 6.6% year on year to $1.21 billion. Guidance for next quarter’s revenue was better than expected at $1.28 billion at the midpoint, 1.8% above analysts’ estimates. Its GAAP profit of $2.91 per share was 26.6% above analysts’ consensus estimates.
Is now the time to buy ANF? Find out in our full research report (it’s free).
Abercrombie & Fitch’s second quarter results slightly exceeded Wall Street revenue expectations, with management crediting strong performance at Hollister and steady traffic across both digital and physical channels. CEO Fran Horowitz highlighted Hollister’s momentum, describing it as “an exciting time, with everything working across categories and genders.” Abercrombie, however, was impacted by lower average unit retail due to inventory clearance, a deliberate move to reset for future growth. Management also noted the continued benefit of new store openings and the positive response to brand activations, especially for Hollister’s heritage and Collegiate collections.
Looking ahead, management’s guidance for the next quarter and the full year reflects confidence in cross-channel traffic growth and ongoing investments in marketing and partnerships. CFO Robert Ball explained that the company is increasing marketing spend to support initiatives like the NFL partnership and fall campaigns, while also navigating tariff headwinds with a well-defined mitigation strategy. Horowitz added, “Our teams have demonstrated before, we have a variety of options in our playbook, including shifting global production, enhancing supplier contracts, managing operating expenses, and determining ways to increase AUR through lower promotions.”
Management attributed the quarter’s performance to Hollister’s strong brand resonance, strategic inventory management, and targeted investments in marketing and retail footprint expansion.
Management expects growth to be driven by sustained traffic gains, continued marketing investments, and strategic responses to supply chain and tariff challenges.
In the coming quarters, the StockStory team will be monitoring (1) the impact of new product launches and brand activations—such as the NFL partnership and expanded denim campaigns—on traffic and sales, (2) Abercrombie’s return to growth as inventory resets take hold and promotional activity normalizes, and (3) the effectiveness of tariff mitigation strategies, including supply chain adjustments and vendor negotiations. Store expansion progress and the ramp of marketing investments will also be important markers of execution.
Abercrombie and Fitch currently trades at $98.06, up from $96.74 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
5 min | |
2 hours | |
8 hours | |
Aug-28 | |
Aug-28 | |
Aug-28 |
Record Urban Outfitters Results Not Enough For Investors. Retailers Mixed.
ANF
Investor's Business Daily
|
Aug-28 | |
Aug-28 | |
Aug-28 | |
Aug-28 | |
Aug-28 | |
Aug-28 | |
Aug-28 | |
Aug-28 | |
Aug-27 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite